Product
LB1901
1 clinical trial
5 indications
Indication
T-cell lymphomaIndication
Peripheral T-Cell LymphomaIndication
Cutaneous T-Cell Lymphoma RefractoryIndication
Cutaneous T-Cell Lymphoma RecurrentIndication
Peripheral T-Cell Lymphoma RecurrentClinical trial
A Phase 1, First-In-Human, Open-Label, Multicenter, Multicohort Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2023-12-01